Immunoglobulin A NephropathyPhase 3PROTECTNCT03762850
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
A Phase 3 study testing sparsentan, irbesartan and Dapagliflozin in people with Immunoglobulin A Nephropathy, run by Travere Therapeutics, Inc. at 162 sites in 18 countries.
Trial summary
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Immunoglobulin A Nephropathy
- What is being tested?
- sparsentan, irbesartan and Dapagliflozin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 406 participants
- Where
- 162 sitesin 18 countries
- Study dates
- 11 Dec 2018to 19 Aug 2026
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older at screening
- Biopsy-proven primary IgAN
- Proteinuria of ≥1 g/day at screening
- eGFR ≥30 mL/min/1.73 m2 at screening
- Currently on stable dose of ACEI and/or ARB therapy, for at least 12 weeks prior to screening (maximum tolerated dose and at least one-half of the maximum labeled dose)
- Systolic BP ≤150 mmHg and diastolic BP ≤100 mmHg at screening
- Willing to undergo change in ACEI and/or ARB and anti-hypertensive medications
- Agree to contraception
Who cannot join
- IgAN secondary to another condition
- Presence of cellular glomerular crescents in >25% of glomeruli on renal biopsy (if biopsy available within 6 months of screening)
- Chronic kidney disease (CKD) in addition to IgAN
- History of organ transplantation, with exception of corneal transplants
- Require any prohibited medications
- Treatment of systemic immunosuppressive medications (including corticosteroids) for >2 weeks within 3 months of screening
Show all 35Show fewer
- History of heart failure or previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and/or peripheral edema
- Clinically significant cerebrovascular disease or coronary artery disease within 6 months of screening
- Jaundice, hepatitis, or known hepatobiliary disease or elevations of transaminases (ALT/AST) >2 times upper limit of normal at screening
- History of malignancy other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma within the past 2 years
- Hematocrit value <27% (0.27 V/V) or hemoglobin value <9 g/dL (90 g/L) at Screening
- Potassium >5.5 mEq/L (5.5 mmol/L) at Screening
- History of alcohol of illicit drug use disorder
- History of serious side effect or allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including sparsentan or irbesartan, or has a hypersensitivity to any of the excipients in the study medications
- For female: Pregnancy, or planning to become pregnant during the course of the study, or breastfeeding
- Participation in a study of another investigational product within 28 days of screening
- Key Inclusion Criteria for the Open-Label Extension Period based on assessments at the Week 110 visit:
- Completed participation in the double-blind period, including the Week 114 visit
- Did not permanently discontinue study medication during the double-blind period
- Agree to contraception
- Key Exclusion Criteria for the Open-Label Extension Period based on assessments at the Week 110 and Week 114 visits:
- Progression to end-stage renal disease (ESRD) requiring renal replacement therapy (RRT)
- Development of any criteria for discontinuation of study medication or discontinuation from the study, between Week 110 and Week 114
- Patient was unable to initiate, or developed contraindications to, treatment with RAAS inhibitors between Week 110 and Week 114
- eGFR ≤20 mL/min/1.73 m2 at Week 110
- Female patient is pregnant or breastfeeding
- Key Inclusion Criteria for the OLE Sparsentan + SGLT2 Inhibitor Sub study:
- Participating in the open-label extension and is willing and able to provide signed informed consent for participation in the open-label extension period Sub study
- A urine protein excretion value of ≥0.3 g/day.
- An eGFR of ≥25 mL/min/1.73m2
- On a stable dose of sparsentan for ≥8 weeks in the open-label extension period that is the maximum tolerated dose.
- Key Exclusion Criteria for the OLE Sparsentan + SGLT2 Inhibitor Sub study:
- Progressed to ESRD requiring RRT
- Initiated or changed dose of a systemic immunosuppressive medication (including systemic steroids) within 12 weeks
- Taking an SGLT2 inhibitor within 12 weeks
Trial locations and contacts
162 sites in 18 countries.
162 sites in 18 countries
United States40 sites
Travere Investigational Site
Birmingham, Alabama, 35233
Travere Investigational Site
Boston, Massachusetts, 02215
Travere Investigational Site
Cleveland, Ohio, 44106
Travere Investigational Site
Columbia, South Carolina, 29203
Travere Investigational Site
Columbus, Ohio, 43210
Travere Investigational Site
Coral Springs, Florida, 33071
Travere Investigational Site
Denver, Colorado, 80230
Travere Investigational Site
El Paso, Texas, 79935
Travere Investigational Site
Fort Worth, Texas, 76104
Travere Investigational Site
Fresh Meadows, New York, 11365
Travere Investigational Site
Glendale, California, 91206
Travere Investigational Site
Hinsdale, Illinois, 60521
Travere Investigational Site
Hollywood, Florida, 33021
Travere Investigational Site
Homewood, Alabama, 35209
Travere Investigational Site
Houston, Texas, 77054
Travere Investigational Site
Kansas City, Kansas, 66160
Travere Investigational Site
Lawrenceville, Georgia, 30046
Travere Investigational Site
Lewisville, Texas, 75057
Travere Investigational Site
Louisville, Kentucky, 40202
Travere Investigational Site
Marshfield, Wisconsin, 54449
Travere Investigational Site
Miami, Florida, 33136
Travere Investigational Site
Miami, Florida, 33186
Travere Investigational Site
Minneapolis, Minnesota, 55404
Travere Investigational Site
Montebello, California, 90640
Travere Investigational Site
Muncie, Indiana, 47303
Travere Investigational Site
Nampa, Idaho, 83687
Travere Investigational Site
New York, New York, 10032
Travere Investigational Site
Northridge, California, 91324
Travere Investigational Site
Philadelphia, Pennsylvania, 19104
Travere Investigational Site
Reno, Nevada, 89511
Travere Investigational Site
Salt Lake City, Utah, 84115
Travere Investigational Site
Salt Lake City, Utah, 84132
Travere Investigational Site
San Antonio, Texas, 78207
Travere Investigational Site
San Diego, California, 92103-6204
Travere Investigational Site
San Diego, California, 92103
Travere Investigational Site
Springfield, Massachusetts, 01104
Travere Investigational Site
Stanford, California, 94205
Travere Investigational Site
Tacoma, Washington, 98405
Travere Investigational Site
Winter Park, Florida, 32789
Travere Investigational Site
Worcester, Massachusetts, 01608
United Kingdom20 sites
Travere Investigational Site
Birmingham, West Midlands, B9 5SS
Travere Investigational Site
Brighton, East Sussex, BN2 5BE
Travere Investigational Site
Cambridge, Cambridgeshire, CB2 0QQ
Travere Investigational Site
Cardiff, West Glamorgan, CF14 4XW
Travere Investigational Site
Carshalton, Surrey, SM5 1AA
Travere Investigational Site
Derby, Derbyshire, DE22 3DT
Travere Investigational Site
Edinburgh, Scotland, EH16 4SA
Travere Investigational Site
Glasgow, Strathclyde, G11 6NT
Travere Investigational Site
Leicester, Leicestershire, LE5 4PW
Travere Investigational Site
Liverpool, L9 7AL
Travere Investigational Site
London, Greater London, E1 4AT
Travere Investigational Site
London, Greater London, SE1 9RT
Travere Investigational Site
London, E1 1FR
Travere Investigational Site
London, SE5 9RS
Travere Investigational Site
Manchester, Greater Manchester, M13 9WL
Travere Investigational Site
Middlesbrough, Cleveland, TS4 3BW
Travere Investigational Site
Preston, Lancashire, PR2 9HT
Travere Investigational Site
Reading, Berkshire, RG1 5AN
Travere Investigational Site
Salford, Greater Manchester, M6 8HD
Travere Investigational Site
Stoke-on-Trent, Staffordshire, ST4 6QG
Spain13 sites
Travere Investigational Site
Barcelona, 08003
Travere Investigational Site
Barcelona, 08025
Travere Investigational Site
Barcelona, 08035
Travere Investigational Site
Barcelona, 08036
Travere Investigational Site
Madrid, 28007
Travere Investigational Site
Madrid, 28040
Travere Investigational Site
Madrid, 28041
Travere Investigational Site
Palma de Mallorca, Balearic Islands, 07120
Travere Investigational Site
Sagunto, Valencia, 46520
Travere Investigational Site
Seville, 41009
Travere Investigational Site
Valencia, 46014
Travere Investigational Site
Valencia, 46017
Travere Investigational Site
Zaragoza, 50009
Australia10 sites
Travere Investigational Site
Adelaide, South Australia, 5000
Travere Investigational Site
Birtinya, Queensland, 4575
Travere Investigational Site
Concord, New South Wales, 2139
Travere Investigational Site
Gosford, New South Wales, 2250
Travere Investigational Site
Kingswood, New South Wales, 2747
Travere Investigational Site
Nedlands, Western Australia, 6009
Travere Investigational Site
New Lambton Heights, New South Wales, 2305
Travere Investigational Site
Randwick, New South Wales, 2031
Travere Investigational Site
Reservoir, Victoria, 3073
Travere Investigational Site
St Leonards, New South Wales, 2065
Germany10 sites
Travere Investigational Site
Aachen, North Rhine-Westphalia, 52074
Travere Investigational Site
Berlin, 10117
Travere Investigational Site
Düsseldorf, North Rhine-Westphalia, 40210
Travere Investigational Site
Hanover, Lower Saxony, 30625
Travere Investigational Site
Jena, Thuringia, 07747
Travere Investigational Site
Kaiserslautern, Rheinland Palatinate, 67655
Travere Investigational Site
Kiel, Schleswig-Holstein, 23538
Travere Investigational Site
Kiel, Schleswig-Holstein, 24105
Travere Investigational Site
Trier, Rheinland Palatinate, 54292
Travere Investigational Site
Villingen-Schwenningen, Baden-Wurttemberg, 78052
Italy10 sites
Travere Investigational Site
Bari, 70124
Travere Investigational Site
Catania, 95123
Travere Investigational Site
Catanzaro, 88100
Travere Investigational Site
Lecco, 23900
Travere Investigational Site
Milan, Lombardy, 20162
Travere Investigational Site
Modena, 41124
Travere Investigational Site
Pavia, 27100
Travere Investigational Site
Ranica, Bergamo, 24020
Travere Investigational Site
Roma, 00168
Travere Investigational Site
Torino, 10126
South Korea10 sites
Travere Investigational Site
Anyang-si, 14068
Travere Investigational Site
Busan, 47392
Travere Investigational Site
Incheon, 21565
Travere Investigational Site
Seongnam-si, Gyeonggi-do, 13620
Travere Investigational Site
Seoul, 02841
Travere Investigational Site
Seoul, 03080
Travere Investigational Site
Seoul, 06273
Travere Investigational Site
Seoul, 110-746
Travere Investigational Site
Seoul, 120-752
Travere Investigational Site
Seoul, 135-710
France8 sites
Travere Investigational Site
Clermont-Ferrand, Puy De Dome, 63003
Travere Investigational Site
Créteil, 94010
Travere Investigational Site
Grenoble, Isere, 38043
Travere Investigational Site
Marseille, Bouches-du-Rhone, 13005
Travere Investigational Site
Montpellier, Herault, 34295
Travere Investigational Site
Paris, Paris, 75015
Travere Investigational Site
Paris, 75475
Travere Investigational Site
Saint-Priest-en-Jarez, Pays de la Loire Region, 42270
Belgium6 sites
Travere Investigational Site
Bonheiden, 2820
Travere Investigational Site
Bruges, 8310
Travere Investigational Site
Ghent, 9000
Travere Investigational Site
Kortrijk, 8500
Travere Investigational Site
Liège, 4000
Travere Investigational Site
Roeselare, 8800
Poland6 sites
Travere Investigational Site
Krakow, 31-559
Travere Investigational Site
Lodz, 93-347
Travere Investigational Site
Olsztyn, 10-124
Travere Investigational Site
Olsztyn, 10-561
Travere Investigational Site
Warsaw, 04-749
Travere Investigational Site
Wroclaw, 50-566
Portugal6 sites
Travere Investigational Site
Coimbra, 3000-075
Travere Investigational Site
Lisbon, 1069-166
Travere Investigational Site
Lisbon, 1649-035
Travere Investigational Site
Loures, 2674-514
Travere Investigational Site
Setúbal, 2910-446
Travere Investigational Site
Vila Nova de Gaia, 4434-502
Hong Kong5 sites
Travere Investigational Site
Hong Kong
Travere Investigational Site
Kwun Tong, Kowloon
Travere Investigational Site
Lai Chi Kok, Kowloon
Travere Investigational Site
Shatin, New Territories
Travere Investigational Site
Tsuen Wan, New Territories
Taiwan5 sites
Travere Investigational Site
Hualien City, 970
Travere Investigational Site
Kaohsiung City, 807
Travere Investigational Site
Kaohsiung City, 81362
Travere Investigational Site
New Taipei City, 220
Travere Investigational Site
Taichung, 40705
New Zealand4 sites
Travere Investigational Site
Grafton, Auckland, 1142
Travere Investigational Site
Hamilton, 3200
Travere Investigational Site
Hastings, 4120
Travere Investigational Site
New Plymouth, 4310
Estonia3 sites
Travere Investigational Site
Tallinn, 10617
Travere Investigational Site
Tallinn, 13419
Travere Investigational Site
Tartu, 50406
Croatia2 sites
Travere Investigational Site
Osijek, 31000
Travere Investigational Site
Zagreb, 10000
Czechia2 sites
Travere Investigational Site
Prague, 10034
Travere Investigational Site
Prague, 12808
Lithuania2 sites
Travere Investigational Site
Kaunas, LT-50009
Travere Investigational Site
Vilnius, LT-08661
About this study
Official title: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Read the detailed description
This is a 114-week,randomized, multicenter, double-blind, parallel-group, active-control study with an open-label extension period of up to 156 weeks, for a total duration of up to 270 weeks in patients with IgAN who have persistent overt proteinuria and remain at high risk of disease progression despite being on a stable dose (or doses) of an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) that is (are) a maximum tolerated dose that is at least one half of the maximum labeled dose (MLD) (according to approved labeling. Approximately 380 patients aged ≥18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan.
The purpose of the study is to evaluate the potential benefit of sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
Patients enrolled in the PROTECT study (Protocol 021IGAN17001) will be those at high risk of progressing to renal failure. They will be randomly assigned in a 1:1 ratio to either sparsentan or irbesartan, as the active control (current standard treatment) at the Day 1 (Randomization) visit. Study medication (sparsentan and irbesartan) will be administered as a single oral morning dose.
The primary analysis is change in proteinuria (urine protein/creatinine ratio) from baseline at Week 36 in sparsentan-treated patients as compared to irbesartan-treated patients.
Primary completion date represents the anticipated completion date of the double-blind portion of the study. Study completion date represents the anticipated completion date of the open-label extension portion of the study.
Patients participating in the open-label extension period may be evaluated for eligibility to participate in a randomized, open-label, controlled Sub study evaluating the safety and efficacy of an SGLT2 inhibitor in addition to stable sparsentan treatment (OLE Sub study). The SGLT2 inhibitor, dapagliflozin will be provided as "study medication" for the OLE Sub study. Following completion of the visit 12 weeks after the OLE baseline visit, eligible patients may receive open-label dapagliflozin for at least 12 weeks but up to 24 additional weeks, or through the end of the open-label extension period, whichever is shortest. Approximately 60 patients from the open-label extension period will be enrolled into the OLE Sub study.
- Conditions
- Immunoglobulin A Nephropathy
- Being tested
- sparsentan, irbesartan, Dapagliflozin
- Medical subject headings
- Glomerulonephritis, IGA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sparsentanDrug
Also called RE-021
Target dose of 400 mg daily
irbesartanDrug
Also called Irbesartan Tablets USP
Target dose of 300 mg daily
DapagliflozinDrug
Target dose of 10 mg daily
| Study group | Role | What they receive |
|---|---|---|
| sparsentan | Experimental | Double-blind: Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400- mg and continue treatment to Week 110. Receives: Drug: sparsentan |
| irbesartan | Active comparator | Double-blind: Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110. Receives: Drug: irbesartan |
| dapagliflozin + sparsentan (Sub study) | Experimental | OLE Sub study: Dapagliflozin will be administered daily as a 5-mg oral tablet, in addition to 400-mg of Sparsentan, for a period of 12 weeks. Receives: Drug: sparsentan; Drug: Dapagliflozin |
| sparsentan (Sub Study) | Experimental | OLE Sub study: Sparsentan will be administered daily as a dose of 400-mg for a period of 12 weeks. Receives: Drug: sparsentan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36
24-hour urine sample was collected for analysis of UP/C via a mixed-model repeated-measures (MMRM) analysis. Missing responses were imputed prior to analysis using multiple imputation. Change from Baseline during the double-blind period in UP/C on the log scale was the dependent variable. Log Baseline UP/C was included as a covariate along with fixed effects for randomized treatment, time (ie, nominal visit in weeks), randomized treatment-by-time interaction, and randomization strata with participants as random effect. Estimates in log scale were back transformed. Baseline was defined as the last non-missing observation on or prior to the start of the dosing. Using Rubin's approach, estimated treatment effects are combined across all imputations to obtain overall estimates.
Measured: Baseline (Day 1) and at Week 36
Secondary outcomes (2)
Total Slope of Estimated Glomerular Filtration Rate (eGFR) Over a 110-week Period
The rate of change in eGFR from Day 1 to Week 110 (ie, over 110 weeks) was analyzed via a mixed-model random coefficients analysis. Missing responses were imputed prior to analysis using multiple imputation. Fixed effects for randomized treatment, Baseline eGFR, time (in weeks), randomized treatment-by-time interaction, and randomization strata were included. In addition, the model also included a random intercept and random slope for each participant. Using Rubin's approach, the estimated treatment effects are combined across all imputations to obtain the overall estimates.
Measured: From Day 1 to Week 110
Annualized Slope of eGFR Following the Initial Acute Effect of Randomized Treatment (Chronic Slope)
The rate of change in eGFR from Week 6 to Week 110 (ie, over 104 weeks following the initial acute effect of randomized therapy) was analyzed via a mixed-model random coefficients analysis. Missing responses were imputed prior to analysis using multiple imputation. Fixed effects for randomized treatment, Baseline eGFR, time (in weeks), randomized treatment-by-time interaction, and randomization strata were included. In addition, the model also included a random intercept and random slope for each participant. Using Rubin's approach, the estimated treatment effects are combined across all imputations to obtain the overall estimates.
Measured: From Week 6 to Week 110 post randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2018
- Study start11 Dec 2018
- Primary completion7 Aug 2023
- Study completion19 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Immunoglobulin A NephropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 406 participants (actual)
Sponsor and investigators
- Lead sponsor
- Travere Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Radko Komers, MD, PhD, Study director, Travere Therapeutics, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03762850
- Sponsor's protocol ID
- 021IGAN17001
- Other IDs
- 2023-505495-30-00, 2017-004605-41, 2017, 2023
- Acronym
- PROTECT
- Status last verified
- Sep 2026
- First submitted
- 27 Nov 2018
- Last updated
- 14 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
Publications
Heerspink HJL, Rovin BH, Komers R, Hendry B, Mercer A, Preciado P, Murphy E, Tesar V. Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. Clin J Am Soc Nephrol. 2026 Apr 1;21(4):578-592. doi: 10.2215/CJN.0000000961. Epub 2025 Dec 22.
PubMed 41428405Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.
PubMed 38299639Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Malecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
PubMed 37931634Obadina M, Wilson S, Derebail VK, Little J. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations. Kidney360. 2023 Jul 1;4(7):997-1005. doi: 10.34067/KID.0000000000000162. Epub 2023 May 31.
PubMed 37254256Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
PubMed 37015244